Bristol Myers Squibb's Camzyos Shows Promise in Adolescent HCM Trial

Event summary

  • Bristol Myers Squibb's Phase 3 SCOUT-HCM trial met primary endpoint, showing significant reduction in Valsalva LVOT gradient in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
  • Camzyos demonstrated meaningful improvements in secondary endpoints, including LV obstruction, diastolic function, and NYHA class, over a 28-week period.
  • The trial enrolled 44 patients aged 12 to <18 years old, with similar safety profiles observed in Camzyos and placebo groups.
  • Results were presented at the American College of Cardiology’s Annual Scientific Session & Expo 2026 and published in The New England Journal of Medicine.

The big picture

Bristol Myers Squibb's positive Phase 3 trial results for Camzyos in adolescents with oHCM represent a significant step in addressing a rare cardiac disorder with no approved therapies. This expansion into the pediatric market underscores the company's leadership in the cardiac myosin inhibitor space and its commitment to reshaping the treatment landscape for hypertrophic cardiomyopathy. The strategic move could enhance Bristol Myers Squibb's market position and drive growth in the cardiovascular disease segment.

What we're watching

Regulatory Approval
Whether the FDA will approve Camzyos for adolescent oHCM based on these trial results.
Market Expansion
The pace at which Bristol Myers Squibb can expand Camzyos into the pediatric market.
Competitive Dynamics
How this approval could position Bristol Myers Squibb against competitors in the cardiac myosin inhibitor space.

Related topics

Pharmaceuticals